Mobile App for Improving Adherence of Rivoxaban (RIVOX-AF)
The ReInforcement of Adherence Via Self-monitoring App Orchestrating Biosignals and Medication of RivoXaban in Patients with Atrial Fibrillation and Co-morbidities: Randomised Control Study(RIVOX-AF Study)
Seoul National University Bundang Hospital
1,042 participants
Mar 10, 2022
INTERVENTIONAL
Conditions
Summary
RIVOX-AF study is a prospective, multicenter, randomized controlled study in which patients with AF are allocated to medication-app group or conventional treatment group. The App based feed-back algorithm will provide the patients with check taking drug or reminding of taking drug.
Eligibility
Inclusion Criteria3
- Patients with AF aged 19 years or older with one or more comorbidities including heart failure, myocardial infarction, stable angina, hypertension or diabetes mellitus (Patients can be enrolled 3 months after myocardial infarction or percutaneous coronary intervention).
- patients who already took or plan to take rivoxban
- patients who able to use smart phone
Exclusion Criteria7
- creatinine clearance \<15ml/min
- moderate or severe mitral stenosis
- mitral valve operation history
- current alcohol abuse or alcohol abus history
- Not eligible for study due to legal or psychiatric problem
- enrolled other clinical study within 4 weeks
- declined to enroll the study
Interventions
MEDI-app based feedback algorithm. The app based feedback algorithm will check and remind the patients of taking medication.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05557123